Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Although ivonescimab plus chemotherapy demonstrates efficacy following EGFR-TKI failure, oncologists display little consensus regarding its treatment line placement. Increased frontline chemotherapy usage from regimens like FLAURA2 creates sequencing dilemmas regarding whether bispecifics belong in the second line or should be reserved for later lines.

Related Insights

The standard first-line treatment for classical EGFR-mutated NSCLC has evolved from osimertinib monotherapy to include two combination strategies: osimertinib plus chemotherapy (FLORA2) and amivantamab plus lazertinib (MARIPOSA). This provides more aggressive options for patients with a higher disease burden or CNS metastases.

The standard of care for newly diagnosed EGFR-mutated non-small cell lung cancer has shifted from osimertinib monotherapy to combination regimens. Experts agree that combinations (e.g., osimertinib/chemo) should be the default choice, with monotherapy now reserved for cases with significant tolerability concerns.

The FLORA two study's overall survival benefit was so compelling that clinicians should now default to osimertinib plus chemotherapy for most first-line EGFR-mutant NSCLC patients, only opting out for specific reasons like comorbidities or patient preference.

Patients with EGFR-mutated lung cancer progressing on frontline TKIs frequently exhibit CNS metastases and historically respond poorly to checkpoint inhibitors. In the HARMONY trial, adding ivonescimab to chemotherapy preserved progression-free survival benefits and actually produced greater additive benefit in patients presenting with brain metastases.

The two leading first-line combination therapies for EGFR-mutated NSCLC, FLORA2 and Mariposa, offer similar survival benefits. The decision often comes down to patient preference and managing distinct side effects: hematologic toxicity versus dermatologic issues and thromboembolic events.

Due to a 10-11 month overall survival benefit shown in the FLORA two regimen, leading oncologists now consider osimertinib plus chemotherapy the standard first-line treatment for metastatic EGFR-mutant NSCLC. Monotherapy is reserved only for patients who cannot tolerate or refuse chemotherapy.

Contrary to expectations from metastatic disease trials like FLAURA2, the NeoAdura study showed that combining chemotherapy with neoadjuvant osimertinib did not yield a better major pathologic response (MPR) than osimertinib alone for resectable EGFR-mutant lung cancer, questioning the role of upfront chemo in this setting.

In the HARMONY A study, Ivanesimab plus chemotherapy significantly improved progression-free survival in EGFR-mutant non-small cell lung cancer patients. This is notable because prior trials showed that adding standard PD-1 inhibitors to chemotherapy was ineffective for this specific patient population.

The long-standing platinum doublet backbone for frontline SCLC may soon be challenged. The high efficacy of novel agents like antibody-drug conjugates and bispecific antibodies in later lines is prompting trials that consider moving them into the first-line setting, a strategy previously considered "unthinkable."

The era of sequential monotherapy is over. Trials like FLORA2 (Osimertinib + chemo) show significant progression-free and overall survival benefits, making intensified upfront treatment the new standard of care for most patients, marking a major paradigm shift in treatment.